During the coronavirus crisis, doctors and healthcare workers are giving absolutely everything in the world’s fight against the epidemic which has claimed more than three lakh lives globally. There are 4.81 million confirmed cases of coronavirus and 1.79 million people have recovered from the deadly outbreak.
Several companies and universities are rushing to create coronavirus vaccines. The condition across the globe is critical but we know–this too shall pass. So amid this situation of crisis, here is good news to give you a sigh of relief.
In good news, American biotechnology company Moderna has announced that it has developed a vaccine to prevent the spread of coronavirus. Yes, you read it right. Moderna has claimed that they have successfully conducted the first human trials.
Moderna said its vaccine, mRNA-1273, was “generally safe and well-tolerated” in its clinical trials of patients, ages 18-55. The study, which is led by the National Institute of Allergy and Infectious Diseases (NIAID), tested three doses: 25 mcg, 100 mcg and 250 mcg.
It has been learnt that Scientists have experimented with the vaccine on mice and found that it prevented viral replication in the animals’ lungs. The coronavirus vaccine has been tested on 45 people, most of them saw their antibody levels rise to about the same level as patients who already recovered from COVID-19, according to the report.
“We believe these two data sets represent an important step forward,” Stéphane Bancel, CEO of Moderna, said in a conference call with reporters.
Moderna said that the initial results of the human clinical trial have been positive. The third phase of the vaccine trial will take place in July. The company has been working on the development of this vaccine since January.
Over 100 vaccines are being studied for COVID-19 infection, and at least eight of these, including Moderna’s, have already progressed to human studies.